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ORIGINAL RESEARCH
Aim: Assess the impact of using academic detailing-assisted guideline roll-out on warfarin
initiation, reversal of warfarin overanticoagulation, and uptake of deep vein thrombosis (DVT)
prophylaxis across 4 metropolitan teaching hospitals.
Methods: Baseline data were collected for 3 months prior to intervention. Prescribers were
then informed about the guidelines, including feedback of current hospital performance and
the basis for the guidelines. Post-intervention data were collected for 3 months after guideline
implementation.
Results: Uptake of DVT prophylaxis in medical patients increased from 52.8% to 67.0%
(p=0.004). No impact on operative surgical patients was seen, possibly due to the high pre-
existing rate of uptake (86.1% vs 84.1%, p=0.7). DVT prophylaxis rates in non-operative
surgical patients were similar to medical patients, with similar, but non-significant
improvements. The time to reach a stable therapeutic international normalized ratio (INR)
after warfarin initiation was reduced (p=0.03) as were the number of INR’s >4 in the first
week of therapy (p=0.03). There were significant improvements in appropriate vitamin K use
for warfarin overanticoagulation in patients with an INR above 6 (48% vs 74%, p=0.007),
timely follow-up tests (49% vs 62%, p=0.009), and the proportion of next INR’s being less
than 4 (49% vs 61%, p=0.04).
Conclusions: The use of academic detailing to facilitate guideline roll-out had a positive
impact on nearly all areas studied. The academic detailing process within the hospital setting
was received enthusiastically by prescribers.
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Introduction
The anticoagulant group of drugs is consistently one of the top drug groups related
to adverse drug events, and the consequences of an adverse event with this group of
drugs is likely to be serious (Wilson et al 1995; Roughhead 1999; Runciman et al
2003). The Australian National Mortality Database from 1997–8 indicated that 2.2%
of patients experienced an adverse event associated with their death, and 25% of
these were drug-related. Anticoagulants accounted for 31% of these adverse drug
events.
Several areas within the anticoagulation practice framework were locally identified
as areas where strategies to encourage prescribers towards best practice may result
in significant improvements in health outcomes. These were:
• Deep vein thrombosis (DVT) prophylaxis in medical patients,
• DVT prophylaxis in surgical patients,
• warfarin initiation,
• treatment of warfarin overanticoagulation.
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The poor uptake of DVT prophylaxis in eligible
hospitalized medical patients remains a consistent
problem across the health system, despite evidence
demonstrating its efficacy. Patient selection, timing and
during of prophylaxis, as well as dosing, remain sources
of confusion for prescribers. The medical literature
reports only 20%–60% of eligible hospitalized medical
patients receive DVT prophylaxis (Anderson et al 1994;
Ageno et al 2002; Bergmann and Mouly 2002; Goldhaber
2003). Adverse consequences of unprevented venous
thromboembolism (VTE) include pulmonary embolism
(PE), death, recurrent DVT, venous valvular
incompetence and chronic post-thrombotic syndrome.
The American Agency for Healthcare Research and
Quality reported in its 2002 practice guidelines that the
highest ranked safety practice to reduce adverse patient
care outcomes was “appropriate use of prophylaxis to
prevent VTE in patients at risk”.
There are clearly clinical consequences from under-
use of DVT prophylaxis. It has been reported that 68%
of hospital-acquired DVT’s or PE’s were potentially
preventable, with 48% not receiving any prophylaxis,
23% receiving an inadequate duration of prophylaxis, and
21% receiving the incorrect type of prophylaxis (Arnold
et al 2001). The importance of post-operative DVT
prophylaxis was highlighted in a group of surgical hip
fracture patients (Todd et al 1995). Twelve of 305 patients
with no DVT prophylaxis succumbed to fatal PE’s
compared with none of the 261 patients who did receive
prophylaxis.
The initiation of warfarin also presents unique
challenges for prescribers. The practice over the last
decade towards warfarin use for patients with atrial
fibrillation has dictated a shift in prescribing to a much
older patient group. This has created a change in how we
approach initiation of warfarin, as we are now treating a
patient group with much higher warfarin sensitivity.
Warfarin initiation approaches that were previously
successful are now clearly too aggressive, and likely to
overanticoagulate the patient (Roberts et al 1999; Gedge
et al 2000). A number of more appropriate methods of
warfarin initiation have since been developed (Oates et
al 1998; Tait and Sefcick 1998, Crowther et al 1999;
Roberts et al 1999).
The management of warfarin overanticoagulation has
also become more clearly defined over the last decade. With
the advent of treatment of a much older patient group,
physicians are more commonly managing patients who
present a challenge with regard to maintaining the
international normalized ratio (INR) in the therapeutic range.
Episodes of overanticoagulation are now well understood
to be associated with serious and sometimes fatal bleeding
events. A number of INR reversal strategies have been
developed which enable timely reduction of the INR back
to the therapeutic range, or if required, total reversal (Wiebert
et al 1997; Wentzien et al 1998).
These are all seemingly relatively simple therapeutic
areas, and prescribing duties for these areas usually rest
at a junior doctor level. Junior medical staff often have
no formal training in these areas, and there is often little
or no coherence across hospitals, or even within hospitals,
towards prescribing. This makes it difficult for junior
prescribers to establish a clear practice in their own mind
by observing the clinical practice around them.
While it is easy to recognize areas of clinical practice
that require improvement, and then draw up practice
guidelines, there are barriers at many levels in the
implementation and practice of these guidelines. Medical
practice is rife with the carcasses of guidelines that have
been distributed and never used. Key barriers consistently
identified include lack of awareness of the guidelines,
inability to access them when needed, and the requirement
for a concise quick-reference format rather than detailed
text (Mortimer and Ward 2002; Scott et al 2003). Other
barriers include lack of agreement with the guidelines,
lack of self-efficacy (belief that one can actually perform
the behaviour), lack of outcome expectancy (the
prescriber doesn’t believe the guidelines will have the
desired effect) and external barriers (Cabana et al 1999).
Clinicians were more motivated to change their practice
when provided with hospital-specific feedback
demonstrating a need for improvement (Anderson et al
1994).
Academic detailing combines a number of techniques
that can be utilized to influence prescribing practices. This
involves a number of principles, such as face-to-face
sessions, preferably on an individual basis, defining clear
educational and behavioral objectives, establishing
credibility with respect to objectivity, stimulating physician
interaction, use of concise graphic educational materials,
highlighting key messages, and when possible, providing
positive reinforcement of improved practices in follow-up
visits (Avorn and Soumerai 1983). This approach has had a
positive impact on prescribing behavior at both the
community and hospital setting (May et al 1999; Solomon
et al 2001).Therapeutics and Clinical Risk Management 2006:2(3) 311
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Methods
Guideline development
Local best-practice guidelines were developed. These
included input from existing published guidelines (SIGN
1999; Geerts et al 2001; Roberts et al 2003), recent primary
literature, and expert opinion from within each of the
targeted hospitals from both key clinical practitioners and
hematologists. Once developed these were then also sent to
the respective hospitals’ drug committees for further
comment and endorsement. This was to help enable
credibility both with respect to objectivity, and with respect
to ownership from local clinical champions. Each guideline
was specifically limited to a single A4 page with an emphasis
on clarity and brevity in order to improve prescriber
acceptance.
Data collection
Prior to the academic detailing intervention, baseline data
for DVT prophylaxis were collected prospectively for a 3
month period, while data on warfarin initiation and treatment
of warfarin overanticoagulation were collected both
retrospectively and prospectively during this 3-month
period. Once the academic detailing was completed, post-
intervention data was collected prospectively for a 3–4
month period.
The academic detailing process
Academic detailing was performed by two pharmacists and
one doctor, all of whom undertook specific training in this
area from experts in the field. The academic detailing process
was not carried out until the baseline data collection was
complete in order to collect unbiased data on current
practice. Prescribers were targeted for one-on-one
interviews, in keeping with the true form of academic
detailing, but larger groups were occasionally catered for
to incorporate the uniqueness of hospital dynamics.
Interviews were conducted at a place of the prescribers’
choice, and took between 20–60 minutes depending on the
level of prescriber interest and prescriber time constraints.
Selected medical and surgical teams at each hospital were
detailed, and only patients treated by these teams were
studied.
The interview was structured to inform the prescriber
why there was a problem in this area and the medical
literature supporting this. An important part of the process
was collation and feedback of local data, indicating the
extent of the problem within that particular hospital. The
guidelines were then introduced, with reference to their
origins, particularly input from any local hospital
champions. They were explained in a clear simple manner,
emphasizing their standardization across the hospitals with
a view to making life easier for the prescriber. Detailing
materials were designed to be clear, brief, easily interpreted,
and where possible presented as graphs.
Key messages
DVT prophylaxis
a) Eligible medical patients defined as those who are
immobilized (temporary or otherwise) in conjunction with
an acute disease process. Patients were considered to be
mobile if they ambulated independently three times daily
for at least 5 minutes each time.
b) Eligible surgical patients determined by adding the risk
associated with both the patient and the type of surgery
c) Low molecular weight heparin (LMWH) dose reduction
or non-LMWH prophylaxis for those patients with impaired
renal function (estimated creatinine clearance <30 ml/min).
Warfarin initiation
a) Use of the guidelines avoids overanticoagulation during
the loading phase
b) Achieves a stable therapeutic INR in a shorter time
c) Use of a recognized initiation approach allows for early
discharge to community physicians.
Warfarin overanticoagulation
a) An INR >6 puts the patient at unacceptable risk and
requires immediate treatment with an appropriate dose of
vitamin K (Hylek et al 2000; Oden and Fahlen 2002).
b) The course of an INR is unpredictable, and timely
follow-up of INR testing after any intervention is essential.
c) Look for signs of bleeding
d) Try and identify the cause of overanticoagulation.
Endpoints
DVT prophylaxis
a) Proportion of eligible patients receiving prophylaxis
b) Uptake of appropriate therapy for patients with reduced
renal function (defined as estimated creatinine clearance
<30 ml/min using optimized Cockroft-Gault equation)
(Kirkpatrick et al 1999). Appropriate alternative therapy was
defined as either a reduced DVT prophylaxis dose of
LMWH, use of unfractionated heparin, or mechanical
prophylaxis.Therapeutics and Clinical Risk Management 2006:2(3) 312
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Warfarin initiation
a) Time to reach a stable therapeutic INR, defined as either
the first of two consecutive INR’s in the range of 2–3, or
the first measurement in the therapeutic range when the
previous or subsequent INR was within 0.5.
b) The number of patients experiencing an INR >4 during
the first week of warfarin initiation.
Warfarin overanticoagulation
a) Use of vitamin K for INR >6
b) Follow-up INR within 24 hours
c) Next INR >4
d) Time between INR being performed and vitamin K
administration for INR’s >6.
An episode of warfarin overanticoagulation was defined as
an INR >4.5
Guideline availability
Guidelines were posted as A4 sheets in critical points on
the wards and in doctors’ offices, prescribers were given
their own pocket-sized charts, electronic copies were
available, and the guidelines were placed in patient drug
charts to enable immediate access at the time of decision
making. Doctors were also given a drug information contact
number specifically for questions regarding the guidelines.
Statistics
Comparison of continuous variables pre and post
intervention utilized a Student’s t-test. Dichotomous
variables were compared with simple non-parametric tests
such as Fisher’s Exact Test. Time to a stable therapeutic
INR was determined using survival analysis, comparisons
being made with the log-rank test.
Sample size
DVT prophylaxis – non-parametric power calculations
indicated at least 120 patients in each group (pre and post
intervention) were required to detect a decrease from 30%
inappropriate prescribing to 15%. No background data was
available for warfarin initiation and treatment of
overanticoagulation. A minimum of 30 patients from each
hospital in each of these categories was collected for the
baseline data.
Results
Patient characteristics are indicated in Table 1.
Medical DVT prophylaxis
During the pre-intervention period 198 patients were
identified as being eligible for DVT prophylaxis,
including 26 patients admitted under surgical teams
for medical reasons. Of these, 180 patients had no
obvious contra-indication for DVT prophylaxis and
were not on oral anticoagulants, with 52.8% receiving
DVT prophylaxis. There were 266 patients assessed
post-intervention, 49 of who were admitted under
surgical teams. Of these, 230 patients had no obvious
contra-indication for DVT prophylaxis and were not
on oral anticoagulants, with 67.0% receiving DVT
prophylaxis, an absolute increase of 14.2% (p=0.004)
(Figure 1).
Table 1 Patient characteristics
Pre- Post-
intervention intervention
Medical DVT prophylaxis
n 198 266
Hospital (%) 23/25/28/24 24/29/25/22
Age (years, mean + 1 SD) 79+10 77+14
Gender (% male) 59 50
Weight (kg, mean + 1 SD)  67+20 70+18
Type of admission (%)
heart failure 24 32
airways disease 32 27
days immobile (median, range) 5.5 (1–225) 5.0 (1–96)
Surgical DVT prophylaxis
n 166 221
Hospital (%) 16/32/22/31 24/32/22/23
Age (years, mean + 1 SD) 70+16 67+18
Gender (% male) 45 45
Weight (kg, mean + 1 SD)  75+18 73+15
Type of DVT surgery (%)
Orthopaedic 44 49
General 44 35
Vascular 9 8
Warfarin initiation
n 173 91
Age (years, mean + 1 SD) 71.4+14.8 72.9+13.5
Gender (% male) 54 47
Weight (kg, mean + 1 SD)  75+19 74+16
Serum albumin 33.5+6.5 33.9+5.1
Hospital (%) 27/21/24/28 30/32/26/12
Warfarin overanticoagulation
Episodes of overanticoagulation 192 106
N 161 89
Age (years, mean + 1 SD) 76+13 78+10
Gender (% male) 47 57
active bleeding (%) 21 14
Abbreviations: DVT, deep vein thrombosis; SD, standard deviation.Therapeutics and Clinical Risk Management 2006:2(3) 313
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When medical and non-operative surgical patients were
considered separately, the trends were similar. For medical
patients in the pre and post-intervention stages, the rate of
DVT prophylaxis uptake was 51.6% and 65.2% respectively
(p=0.016). This was compared with 61.9% and 73.5%
respectively in the small sample of non-operative surgical
patients (p=0.3).
Patients with poor renal function (glomerular filtration
rate [GFR] <30  ml/min) were considered ineligible for full
LMWH DVT prophylaxis. Appropriate therapy was
considered to be either a reduced dose of LMWH, use of
unfractionated heparin or use of mechanical prophylaxis.
During the pre-intervention phase 7 of 21 patients (33%)
received appropriate therapy alteration compared with 19
of 32 (59%) in the post-intervention phase (p=0.3), (Figure
1).
Surgical DVT prophylaxis
During the pre-intervention phase 136 of 158 (86.1%)
clearly eligible patients received prophylaxis, compared
with 174 of 207 (84.1%) in the post-intervention phase
(p=0.7) (Figure 1). Appropriate therapy for patients with
impaired renal function was given for 12 of 22 patients
(55%) in the pre-intervention phase compared with 7 of
13 patients (54%) after the intervention (p=0.98).
Operative surgical patients also received a significantly
higher use of mechanical DVT prophylaxis compared
with medical patients. This was nearly always in
combination with pharmacologic prophylaxis and was
evident during both the pre and post-intervention stages
(p<0.001 for both, see Table 2).
Warfarin overanticoagulation
Use of vitamin K to reverse INR’s >6 in patients with no
clinically obvious bleeding increased from 48.1% in the pre-
intervention phase to 74.4% post-intervention (p=0.007).
The median time taken to administer vitamin K was 13.3
hours before the intervention, decreasing to 7.2 hours after
the intervention (p=0.099) in this group. The next INR taken
was below 4 in 48.7% of patients pre-intervention compared
with 61.1% after the intervention (p=0.04). A follow-up INR
was performed within 24 hours in 48.7% of cases pre-
intervention compared with 62.4% after (p=0.009). For
patients experiencing some form of bleeding, use of vitamin
K increased from 40% to 67% (p=0.17), with no change in
the median time to administer vitamin K (3.7 vs 3.9 hours).
Warfarin initiation
Post-intervention patients initiated on warfarin were quicker
to get to a stable therapeutic INR (p=0.03, see Figure 2).
They were also less likely to experience an episode of
overanticoagulation in the first week of initiation (31.8%
vs 18.7%, p=0.03).
Discussion
With the exception of DVT prophylaxis for the operative
surgical patients, there were clear improvements in the
outcome indicators in all areas. While the endpoints were
not direct measures of patient safety outcomes, it is
reasonably expected they would have a positive flow-on
effect for patient safety. It is likely the improved DVT
prophylaxis uptake would translate to a decreased number
of hospital-acquired DVT, a situation illustrated by Arnold
and colleagues (2001).
The improvements from more aggressively reversing
INR’s >6 and paying closer attention to timely follow-up
Table 2 Modality of DVT prophylaxis
LMWH Heparin Mechanical Combination
only only only mechanical
(%) (%) (%) plus drug(%)
Pre-intervention
Medical 55 22 5 18
1
Surgical 31 9 2 58
Post-intervention
Medical 57 21 5 16
1
Surgical 45 12 3 40
Note: 
1p<0.001 compared with surgical use of mechanical plus drug DVT
prophylaxis.
Abbreviations: DVT, deep vein thrombosis; LMWH, low molecular weight
heparin.
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Figure 1 DVT prophylaxis outcomes (p<0.01).
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may be expected to translate to a decreased likelihood of
bleeding as a serious adverse event (Hylek et al 2000; Oden
and Fahlen 2002). The same might be expected of the
decreased number of high INR’s during warfarin initiation
bought about by use of the guidelines.
The baseline rate of medical DVT prophylaxis uptake
was similar or better than that found by other groups.
Anderson et al (1999) noted a 21%–40% baseline uptake in
a study performed in the late 1980’s when there was possibly
less awareness of this issue. Ageno et al (2002) noted a 46%
uptake in Italian hospitals on a background of passive
guideline dissemination, while a 32% uptake in medical
patients was noted in France (Bergmann and Mouly 2002).
The uptake rates in this study at baseline were marginally
better, but consistent with these figures at 52.8%, a number
based on patients who had a clear indication for DVT
prophylaxis with no contra-indications to prophylaxis and
no other ongoing therapeutic anticoagulation. The increase
to 67.0% after guideline implementation was pleasing, but
indicates there is still room for further improvement.
This study noted a far superior uptake of DVT
prophylaxis in operative surgical patients compared with
that in medical patients. This was 86.1% versus 52.8% at
baseline, and 84.1% versus 67.0% after guideline
implementation, for surgical and medical patients
respectively (p<0.001 for both). This difference has been
noted previously and may be due to the more structured,
protocol-driven nature of procedural surgery that allows
prescribers to pre-empt the need for DVT prophylaxis
(Goldhaber 2003; Goldhaber and Tapson 2004). This
decreased markedly in non-operative patients admitted
under surgical teams, who experienced a similar rate of DVT
prophylaxis uptake as medical patients (62% and 74% DVT
prophylaxis uptake before and after guideline
implementation).
The number of patients experiencing overanti-
coagulation during the first week of warfarin initiation
decreased with the implementation of the warfarin initiation
guidelines, in conjunction with a small improvement in the
time to reach a stable therapeutic INR. However both these
endpoints fell far below what has been shown to be
achievable with these guidelines previously (Roberts et al
2003).
Possibly the most impressive impact was seen with the
warfarin overanticoagulation guidelines. This was possibly
a reflection that these were the simplest, and clearest of the
four guidelines. There were only 2 factors to focus on: the
patients INR, and whether the patient was experiencing
clinically significant bleeding. It is well recognized that
prescribers are more likely to follow guidelines if they are
specific (Michie and Johnston 2004). This excellent uptake
may also have been driven by the clear message from the
academic detailing process that highlighted the increasing
risk of death/hemorrhage with increasing INR’s (Oden and
Fahlen 2002). The prescriber is also “rewarded” within a
relatively short timeframe after an intervention with this
guideline, via noting the satisfactory reduction in INR. With
the other guidelines, there was no obvious or immediate
feedback to the prescriber indicating the new course of action
was having an impact, eg, increased prescribing for DVT
prophylaxis.
Despite the satisfactory improvement in practice as a
result of this form of guideline implementation, several
issues need to be addressed. At all hospitals the rotation of
junior medical and surgical staff, who are likely to do the
bulk of the prescribing for issues related to these guidelines,
is at least three-monthly. This can be even more frequent
when some staff are on holidays, sick leave, etc. The
academic detailing relies of course on timely interaction with
those who are likely to prescribe, which dictates an ongoing
commitment and the resources to do this. The second issue
is that there was still a lot of room for improvement,
especially for the medical patient DVT prophylaxis and the
warfarin initiation. The only approach that has come close
to 100% compliance involves computerization, often with
forcing functions. This has worked particularly well in the
setting of surgical DVT prophylaxis, where admissions are
generally planned, and the need for prophylaxis is pre-
empted (Mosen et al 2004). This is more difficult for the
acute and somewhat more random nature of medical patient
admission.
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The approach of using academic detailing within the
hospital setting was greeted with almost unanimous
enthusiasm. A sample of 36 doctors was taken to judge the
interest in the concept of academic detailing within hospitals,
the interest in anticoagulation as a topic, and their general
participation in the visit. On a scale of 0 (hostile) to 4 (very
interested) the mean ranking was 3.5, 3.6, and 3.7
respectively for each of these areas. Prescribers were very
interested in the feedback from within their own hospitals,
and this undoubtedly helped in their acceptance of the
guidelines. The more junior prescribers were very keen to
absorb this information and found it most useful, as the need
for education in the areas covered by the guidelines was
not being formally met elsewhere. There were occasional
barriers to guideline acceptance, and this appeared more
likely in the senior ranking prescribers, who are possibly
less likely to make a change in their set prescribing habits if
this was required. Resistance to guideline acceptance was
also encountered when the occasional individual consultant
had a very set approach to a particular therapy, eg, using
10 mg, 10  mg, and 5 mg on the first 3 days of warfarin
initiation.
Ideally, academic detailing would be performed each
time a new prescriber (or more commonly, group of
prescribers) commenced at the hospital, so sustainability
issues would need to be considered. It may be more likely
to have a long term effect on younger prescribers, who are
often still seeking input and clarification on clinical issues,
in order that they may develop an appropriate clinical
approach. They are also the group most likely to be doing
the prescribing. Academic detailing appears to be an
effective approach welcomed by prescribers for encouraging
uptake of clinical guidelines within the hospital setting. It
should be strongly considered either by itself or in
conjunction with other strategies as a means of improving
guideline compliance and patient care within the hospital
setting.
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